NX-5948 is under clinical development by Nurix Therapeutics and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase I drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NX-5948’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NX-5948 is under development for the treatment of B-cell malignancies like non-Hodgkin lymphomas including relapsed and refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), Waldenstrom macroglobulinemia (WM) and primary central nervous system lymphoma (PCNSL) or secondary CNS lymphoma, rheumatoid arthritis and graft versus host disease (GvHD) and autoimmune diseases. It is administered through oral route. The drug candidate is a heterobifunctional PROTAC (proteolysis-targeting chimera) which acts by targeting Bruton’s tyrosine kinase (BTK) and cereblon (CRBN).
Nurix Therapeutics overview
Nurix Therapeutics, formerly Nurix Inc, is a biopharmaceutical company that discovers, develops and commercializes small molecule drugs to treat cancer and autoimmune diseases. It is investigating NX-2127, a Bruton’s tyrosine kinase (BTK) inhibitor against B-cell malignancies; NX-5948 drug for the treatment of B-cell malignancies and autoimmune diseases; NX-1607, a ligase inhibitor for immune-oncology indications; and DeTIL-0255 program targeting tumor infiltrating lymphocytes. The company is also evaluating KINASE-CTM3 against T-cell malignancies and autoimmune diseases; and COVID-CTMs for anti-viral infections. Nurix employs DELigase platform technology to modulate targeted proteins and also destroy disease-causing proteins by harnessing the activity of specific E3 ligases. The company works in collaboration with Sanofi and Gilead Sciences to develop its products. Nurix is headquartered in San Francisco, California, the US.
For a complete picture of NX-5948’s drug-specific PTSR and LoA scores, buy the report here.